scholarly journals Bronchomed Balsam as a Remedy of Choice for Pathogenetic and Symptomatic Therapy of Acute Inflammatory Diseases of Respiratory System in Humans

2020 ◽  
pp. 70-74
Author(s):  
D.V. Maltsev ◽  
Keyword(s):  
Respiratory System ◽  
Viral Infections ◽  
Conflicts Of Interest ◽  
Shikimic Acid ◽  
Oxide System ◽  
Symptomatic Therapy ◽  
Therapeutic Effects ◽  
Herbal Preparation ◽  
Respiratory Viral Infections ◽  
Anti Inflammatory

Pathogenetic and symptomatic therapy of acute viral infections of the respiratory system has been a stumbling block of modern therapeutic approaches for this pathology. Bronhomed Balsam is a combined herbal preparation with pathogenetic and symptomatic action, which is used for colds of the respiratory tract. This preparation has antimicrobial, mucolytic, bronchodilator, expectorant, anti-inflammatory, sedative and diaphoretic effect. This review presents the discussion of the composition of the preparation in the context of therapeutic effects of its components. In the focus of attention is anise oil, which contains such active ingredients as anethole, shikimic acid and lignin-carbohydrate-protein complexes, which have antimicrobial and immunomodulatory effects. Another point discussed is the effect of anise oil on the nitric oxide system and the production of interferon gamma, which are important components of the anti-inflammatory and antimicrobial action of the preparation. It has been established that the inclusion of the combined herbal preparation Bronchomed Balsam in the complex of treatment of patients with acute respiratory viral infections allows to effectively stop major symptoms of the disease (in the absence of serious side effects), which indicates the therapeutic efficacy of and good tolerance of to the phytobalm. The therapeutic effect of Bronchomed Balsam is due to its anti-inflammatory, immunomodulatory, expectorant and antiseptic action. This allows to reduce the drug load on the patient's body and to optimize the symptomatic and pathogenetic treatment of acute respiratory viral infections. The author declares no conflicts of interest. Key words: Bronchomed Balsam, acute respiratory viral infections, anise oil.

scholarly journals Acute respiratory infections in children: current trends in antiviral therapy

2021 ◽  
pp. 61-66
Author(s):  
I.I. Andrikevych ◽  
Keyword(s):  
Young Children ◽  
Viral Infections ◽  
Conflicts Of Interest ◽  
Respiratory Infections ◽  
Antiviral Effect ◽  
Symptomatic Therapy ◽  
Sex Structure ◽  
Group I ◽  
Respiratory Viral Infections ◽  
Primary Health Care Centers

The aim is тto study the clinical efficacy of Flavovir® in the treatment of acute respiratory viral infections (ARVI) in young children. Materials and methods. The study included 60 young children who received outpatient treatment at the primary health care centers of the Vinnytsia region in the period from 2019 to 2021. The inclusion criteria for the study were ARVI and age аfrom 1 month to 3 years; exclusion criteria were еaggravated premorbid background (immunodeficiency diseases, congenital malformations, etc.), the use of other antiviral drugs, influenza vaccination. According to this aim the children are divided into two groups. The first group consisted of 30 children with ARVI who received Flavovir® (Research and Production Company "Ecopharm" Ltd, Ukraine) in combination with symptomatic therapy. The second group consisted of 30 patients with ARVI who received only symptomatic therapy. The distribution of patients into groups was carried out randomly. The groups were representative for age, sex, structure and severity of disease. Results. During the study the drug Flavovir® showed an effective antiviral effect in the treatment of acute respiratory viral infections in young children. In ase of the introduction of Flavovir® in the treatment regimen of the examined patients, a positive dynamics of clinical disease was noted: the intoxication syndrome disappeared three times faster (Group I — duration on average 3.4±0.2 days; Group II — 10.4±0.6 days , p<0.05), catarrhal syndrome disappeared approximately two times faster (group I — duration on average 4.5±0.4 days; II group — 9.6±0.7 days, p<0.05); нthere was a reduction in the recovery time by almost two times (group I — on average 5.81±0.5 days, II group — 11.8±0.6 days, p<0.05). The drug is well tolerated by patients and safe for children. Conclusions. The results obtained allow to recommend Flavovir® in age-specific doses for the etiotropic therapy of modern acute respiratory viral infections in young children, taking into account the direct antiviral effect of the drug. The study was carried out in accordance with the principles of the Declaration of Helsinki. The informed consent of the parents of the children was obtained for the research. The author declares no conflicts of interest. Key words: children, treatment, acute respiratory viral diseases, Flavovir.

scholarly journals Evaluation of the effectiveness of ARVI treatment regimen including etiotropic (enisamium iodide) and symptomatic treatment

2020 ◽  
Vol 92 (3) ◽  
pp. 50-55
Author(s):  
D. A. Lioznov ◽  
E. J. Karnaukhova ◽  
T. G. Zubkova ◽  
E. V. Shakhlanskaya
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Antiviral Drug ◽  
Main Group ◽  
Average Score ◽  
Control Group ◽  
Symptomatic Therapy ◽  
Respiratory Viral Infections

Aim. To assess the effectiveness of the use of the antiviral drug enisamium iodide in the complex treatment of acute respiratory viral infections (ARVI) caused by various pathogens in routine clinical practice. Materials and methods. А prospective randomized study included 134 patients who were treated in the epidemic season of influenza and ARVI in 20182019. All patients were examined for the presence of influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, rhinoviruses, adenoviruses in nasopharyngeal swabs by PCR. Patients of the main group received enisamium iodide along with symptomatic therapy, the control group received only symptomatic therapy. The primary parameter of the effectiveness of therapy was evaluated on the scale of the general severity of the manifestations of ARVI (Total Symptom Score TSS) from the 2nd to the 4th day and by the secondary criteria of effectiveness: assessment of the duration of ARVI, the severity of fever, the proportion of patients with normal body temperature, the duration of the main clinical symptoms of acute respiratory viral infections, the proportion of patients in whom complications requiring antibiotics were noted, the dynamics of interferon status on the 6th day. To conduct a statistical analysis, depending on the efficiency parameter, the ANCOVA method with a fixed group factor and an initial score on the TSS severity scale was used as covariates, a criterion for comparing quantitative indicators in two independent groups. Results. According to the results of the analysis of the primary efficacy parameter, the median (interquartile range) of the average score on the scale of the general severity of ARVI manifestations in the main group was 4.33 (3.675.83), in the comparison group 6.00 (4.677.25; p0.001). The duration of systemic and local manifestations of acute respiratory viral infections was statistically significantly less in the main group (p=0.002 and p=0.019, respectively). Prescription of additional therapy was required in 2 (2.9%) patients of the main group (patients taking enisamium iodide), compared with 8 (11.9%) patients in the control group. Serum levels of interferon  and interferon  on the last day of treatment were statistically significantly higher in patients of the main group compared with the control group (p0.001). Treatment (excellent) was evaluated by 42 (62.7%) patients, while in the control group only 17 (25.8%) patients gave similar ratings. Both patients (p0.001) and doctors (p0.002) rated therapy tolerance better in the study group. Conclusion. The results confirmed the safety and effectiveness of enisamium iodide as a treatment for ARVI and influenza. The antiviral, interferonogenic and anti-inflammatory properties of the drug are involved in the formation of an antiviral response and reduce the risk of complications, which makes it possible to reduce the number of symptomatic agents used.

scholarly journals New prospects for local etiotropic treatment of acute respiratory viral infections

2019 ◽  
pp. 105-108
Author(s):  
A. A. Krivopalov ◽  
V. A. Shatalov ◽  
S. V. Shervashidze
Keyword(s):  
Respiratory Tract ◽  
Respiratory System ◽  
Safety Profile ◽  
Viral Infections ◽  
Inflammatory Diseases ◽  
Upper Respiratory Tract ◽  
Positive Experience ◽  
High Efficacy ◽  
Upper Respiratory ◽  
Respiratory Viral Infections

According to WHO, the respiratory system diseases are currently inside the ten most common pathologies. The modern strategy for treating influenza and ARVI gives priority to the antiviral and immunostimulating agents, but the symptomatic drugs, which include preparations based on silver and its compounds, also play an important role. The large positive experience in using silver preparations supported by numerous clinical studies shows their high efficacy and satisfactory safety profile in the treatment of infectious and inflammatory diseases of the nose and upper respiratory tract in children and adults.

scholarly journals Acute respiratory viral infections: possibilities of symptomatic therapy of patients

2021 ◽  
pp. 103-111
Author(s):  
G. N. Nikiforova ◽  
V. M. Svistushkin ◽  
A. V. Zolotova ◽  
M. A. Morozova
Keyword(s):  
Viral Infections ◽  
Symptomatic Therapy ◽  
Nasal Breathing ◽  
General Weakness ◽  
Rapid Changes ◽  
Acute Respiratory Diseases ◽  
Respiratory Viral Infections ◽  
Instructions For Use ◽  
Combined Drugs

Acute respiratory viral infections are widespread in the human population. High contagiosity, a wide variety of pathogens, the possibility of rapid changes in the genotype of the virus and, accordingly,cause the development of drug resistance, make it possible to develop epidemics, and sometimes pandemics of SARS.The clinical picture of all acute respiratory diseases consists of local and general manifestations. Local symptoms include difficulty in nasal breathing, rhinorrhea, pain and discomfort in the throat, cough, hoarseness, stuffy ears, and lacrimation. General manifestations of SARS indicate the onset of viremia, and include an increase in body temperature, general weakness, fatigue, malaise, and headache. The mechanism of SARS development determines the  treatment tactics, including etiotropic, pathogenetic and symptomatic therapy.Domestic and international clinical recommendations indicate the  possible use of  symptomatic agents for  SARS and influenza.Symptomatic treatment is one of the areas of therapy for patients with influenza and other acute respiratory viral infections and allows you to alleviate the general condition, accelerate recovery and improve the quality of life of patients. The use of combined drugs is safer for patients thenthanmonocomponent drugs, and is safe for patients, in case the instructions for use are strictly observed. Such complex medicines, which provides control of the symptoms of colds and flu within 24 hours, as domestic drug are used for patients with SARS. Due to its components, drughas antipyretic, anti-inflammatory, analgesic, anti-allergic, angioprotective and vasoconstrictive effects. The synergism of the components of the combined drug allows to increase the effectiveness of therapy of patients with acute respiratory viral infections.

scholarly journals The assessment of the rationality of the pharmacotherapy of acute respiratory viral infection in the outpatient practice

2021 ◽  
Vol 7 (1) ◽  
pp. 36-41
Author(s):  
O. P. Balitska ◽  
Yu. M. Hryhoruk ◽  
M. A. Artemchuk ◽  
V. S. Zlahoda V. S.
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Family Doctor ◽  
Evidence Base ◽  
The State ◽  
Symptomatic Therapy ◽  
Clinical Protocol ◽  
Family Doctors ◽  
Respiratory Viral Infections ◽  
Outpatient Practice

Acute respiratory viral infections (ARI) and influenza occupy a leading place in the structure of the overall morbidity of the population in most countries. Aim. To assess the rational prescription of drugs for etiotropic therapy of ARI in the outpatient practice. Materials and methods. The following materials for research were used: case histories; treatment sheets; the Unified clinical protocol of primary care for adults and children “Acute respiratory infections”; data of the State Formulary of Medicines as of January 2021; the Register of wholesale prices; the weekly “Apteka” (Pharmacy). The methods of retrospective, descriptive, frequency, and VEN-analysis were applied. Results. According to the research results, using patient histories, it was found that family doctors prescribed 67 drugs by trade names. For etiotropic therapy, 24 drugs were used; it was 37 % of the total number, and 63 % – for symptomatic therapy. Such drugs as Amizon, Aflubin, Amixin, Resistol, Umkalor were for etiotropic therapy (more than 5 prescriptions). None of these drugs is included in the State Formulary of Medicines and the Unified clinical protocol for the treatment of influenza and SARS. Thus, these drugs are without the proven efficiency, safety and cost-effective use. Conclusions. The study conducted has shown that the drugs prescribed most often do not have an evidence base of efficacy and safety; none of the most frequently prescribed drugs is included in the State Formulary of Medicines and the Unified clinical protocol. A direct relationship between an increase in the number of prescriptions and an increase in price has been proven. Key words: acute respiratory viral infections; influenza; frequency analysis; VEN-analysis; family doctor.

scholarly journals Rationale for the symptomatic therapy of respiratory viral infections in children

2019 ◽  
pp. 117-122 ◽  
Author(s):  
T.O. Kryuchko ◽  
◽  
T.V. Kushnereva ◽  
V.P. Harshman ◽  
N.V. Kuzmenko ◽  
...  
Keyword(s):  
Viral Infections ◽  
Symptomatic Therapy ◽  
Respiratory Viral Infections

scholarly journals Acute respiratory viral infections in children

2019 ◽  
Vol 23 (3) ◽  
pp. 19-22
Author(s):  
Irina E. Moiseeva
Keyword(s):  
Respiratory Tract ◽  
General Condition ◽  
Viral Infections ◽  
Clinical Manifestations ◽  
Symptomatic Therapy ◽  
Upper Respiratory Tract ◽  
Child Morbidity ◽  
Upper Respiratory ◽  
Respiratory Viral Infections ◽  
Instrumental Methods

Acute respiratory viral infections in children lead in the structure of child morbidity. The defeat of the upper respiratory tract accompanied by fever and impaired general condition, the main symptoms of acute respiratory viral infections. Diagnosis of most acute respiratory viral infections is based on the assessment of clinical manifestations and does not require the use of specific laboratory and instrumental methods. Modern approaches to treatment are timely and adequate symptomatic therapy.

scholarly journals Non-specific prevention of infections in children

2016 ◽  
Vol 1 (1) ◽  
pp. 114-117
Author(s):  
N. L. Kunelskaya ◽  
A. Y. Ivoylov ◽  
M. I. Kulagina ◽  
V. R. Pakina ◽  
V. V. Yanovskiy ◽  
...  
Keyword(s):  
Respiratory System ◽  
Viral Infections ◽  
Developed Countries ◽  
Passive Immunity ◽  
Economic Damage ◽  
First Year ◽  
Acute Respiratory Disease ◽  
Respiratory Viral Infections ◽  
Prevention Of Infections ◽  
First Year Of Life

ARVI (acute respiratory viral infections, also often called ARD - acute respiratory disease) is a group of diseases that are similar in character and mostly characterized by a pathology of the respiratory system. If the pathogen is not identified, the patient is usually diagnosed with ARD, since the agent is not necessarily a virus. In developed countries, 18% of children aged 1--4 years suffer from acute respiratory viral infections [1]. Children aged 3 to 14 years suffer from ARVI most often. At the same time, children in the first year of life are practically not affected by acute respiratory viral infections. This is contributed by passive immunity which is acquired at birth and maintained during the first months of life thanks to breastfeeding. Influenza and ARVI account for 90% of all infectious pathologies and are the second leading cause of death from infectious diseases [2]. Delayed influenza mortality during epidemics can reach 100 cases per 100 thousand people [3]. Influenza epidemics cause enormous economic damage: in Russia, it equals more than 20 billion rubles each year [4].

Naproxen – a multifunctional drug in the light of current research and reports

2021 ◽  
Vol 14 (3) ◽  
pp. 310-314
Author(s):  
Iwona Sarzyńska-Długosz ◽  
Bartosz Sapilak
Keyword(s):  
Primary Care ◽  
Chronic Diseases ◽  
Musculoskeletal Pain ◽  
Primary Care Physicians ◽  
Viral Infections ◽  
Therapeutic Effects ◽  
Pharmacological Properties ◽  
Effective Reduction ◽  
Anti Inflammatory ◽  
Effective Use

The therapeutic effects of naproxen and its unique pharmacological properties allows it to use not only in the practice of primary care physicians, but also in specialist clinics. Naproxen is effective in relieving musculoskeletal pain of various origins, and additionally has anti-inflammatory and antipyretic properties. This enables its effective use in chronic diseases such as: RA, OA, AS, as well as for effective reduction of symptoms of classic infections, especially viral infections, reducing pain in muscles, joints, head and lowering fever.

Arguments in favor of the use of modern blockers of H1-histamine receptors for the treatment of patients with allergic rhinitis occurring against the background of acute respiratory viral infection

2021 ◽  
Vol 20 (6) ◽  
pp. 125-135
Author(s):  
A. Yu. Ovchinnikov ◽  
◽  
N. A. Miroshnichenko ◽  
Yu. O. Nikolaeva ◽  
◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Viral Infections ◽  
Adult Population ◽  
Allergic Diseases ◽  
Therapeutic Effects ◽  
Upper Respiratory Tract ◽  
Therapy Regimen ◽  
Nasal Symptoms ◽  
Respiratory Viral Infections

Allergic rhinitis is characterized by a significant prevalence among the adult population. Patients with allergic diseases have a higher sensitivity to pathogens of acute respiratory infection of the upper respiratory tract (ARVI). Inflammation of the mucous membrane of the nasal cavity and paranasal sinuses in such patients is characterized by more pronounced symptoms and greater resistance to therapy. An observational study was conducted at the Department of Otorhinolaryngology of the Moscow State Medical University named after A. I. Evdokimov, during which the effect of modern antihistamines on the severity of nasal and non-nasal symptoms of inflammation was evaluated in patients who were diagnosed with the development of acute respiratory viral infections against the background of seasonal exacerbation of allergic rhinitis. The data of 50 patients divided into two groups were analyzed. In the first group (n = 25), benzhydrylpiperazinylbutylmethylxanthine succinate (Theoritin) was included in the therapy regimen, in the second – cetirizine preparations (n = 5). During the follow-up, each patient underwent a clinical assessment of the severity of nasal and non-nasal symptoms three times (1st, 7th and 14th days of follow-up), and the severity of nasal obstruction was assessed using anterior active rhinomanometry. According to the data obtained, there was a pronounced positive dynamics in both groups, while the clinical efficacy was confirmed by instrumental evaluation data. However, by the 7th day of treatment, the positive dynamics was more pronounced in the group of patients receiving theoritin as part of therapy. The use of modern antihistamines in patients comorbid for allergic rhinitis and acute respiratory diseases has a significant therapeutic effect. Theoritin provides more pronounced therapeutic effects in the early stages, which makes its further study and use of the drug for the treatment of acute respiratory viral infections against the background of allergic rhinitis promising.

Sign in / Sign up

Export Citation Format

Share Document